Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Alnylam Pharmaceuticals, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.0B | |
|---|---|---|
| P/E (forward) | 21.1x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.04B | $1.83B | $2.25B | $3.71B | +53.0% |
| Gross profit | $868.6M | $1.52B | $1.92B | $3.03B | +51.7% |
| Operating income | $-971.0M | $-312.3M | $-235.5M | $575.8M | — |
| Net income | $-1.13B | $-440.2M | $-278.2M | $313.7M | — |
| EPS (diluted) | $-9.30 | $-3.52 | $-2.18 | $2.33 | — |
| EBITDA | $-926.6M | $-258.2M | $-178.8M | $631.4M | — |
| R&D | $883.0M | $1.00B | $1.13B | $1.32B | +14.3% |
| SG&A | $770.7M | $795.6M | $975.5M | $1.21B | +16.3% |
Recent company headlines from major financial publishers.
RNAi becomes the standard of care for massive prevalent indications like hypertension and obesity. Operating margins blow past 35% due to hyper-scale manufacturing efficiencies.
ALNY successfully bridges its rare disease dominance into prevalent markets, achieving extreme operating leverage and commanding a premium platform multiple.
| Ke ↓ / g → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 5.0% | $936 | $1,165 | $1,165 | $1,165 | $1,165 |
| 6.0% | $666 | $778 | $936 | $1,165 | $1,165 |
| 7.0% | $516 | $582 | $666 | $778 | $936 |
| 8.0% | $422 | $464 | $516 | $582 | $666 |
| 9.0% | $366 | $386 | $422 | $464 | $516 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
